Difficulty: Medium
Average Score: 72%
Practice
Pyridostigmine differs from neostigmine in that
Correct answer
B
Rationale
In this question, the correct answer is B) Longer acting. Pyridostigmine differs from neostigmine in that it has a longer duration of action. This is due to its slower rate of hydrolysis by acetylcholinesterase compared to neostigmine. This makes it particularly useful in conditions where prolonged cholinergic stimulation is required, such as in myasthenia gravis.
Option A) More potent orally is incorrect because pyridostigmine is not necessarily more potent orally compared to neostigmine. Potency refers to the concentration of a drug required to produce a specific effect, which may vary based on the individual patient's response.
Option C) Less muscarinic side effects is incorrect because both pyridostigmine and neostigmine are reversible acetylcholinesterase inhibitors, and their side effect profiles are quite similar, primarily involving excessive cholinergic stimulation at muscarinic receptors.
Option D) All of the above is incorrect because while pyridostigmine is longer acting than neostigmine, it does not necessarily mean it is more potent orally or has fewer muscarinic side effects.
Understanding the differences between these drugs is crucial for healthcare professionals, especially those involved in managing conditions like myasthenia gravis. Knowing the unique characteristics of each medication helps in making informed decisions about their use based on patient-specific factors and desired outcomes.
Option A) More potent orally is incorrect because pyridostigmine is not necessarily more potent orally compared to neostigmine. Potency refers to the concentration of a drug required to produce a specific effect, which may vary based on the individual patient's response.
Option C) Less muscarinic side effects is incorrect because both pyridostigmine and neostigmine are reversible acetylcholinesterase inhibitors, and their side effect profiles are quite similar, primarily involving excessive cholinergic stimulation at muscarinic receptors.
Option D) All of the above is incorrect because while pyridostigmine is longer acting than neostigmine, it does not necessarily mean it is more potent orally or has fewer muscarinic side effects.
Understanding the differences between these drugs is crucial for healthcare professionals, especially those involved in managing conditions like myasthenia gravis. Knowing the unique characteristics of each medication helps in making informed decisions about their use based on patient-specific factors and desired outcomes.